Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Reduction in the deposition of amyloid β (Aβ) has been the primary target for Alzheimer's disease (AD) therapeutics recently, but in clinical trials this approach has generally been unsuccessful. A common feature of AD pathology is a complex inflammatory component that could be a target for treatment. One feature of this inflammation has been the involvement of the receptor for advanced glycation endproducts (RAGE), whose ligands include advanced glycation-endproduct-modified proteins as well as lipids and Aβ, which are found at elevated levels in AD brains. AREAS COVERED: In this article, the authors describe the key features of RAGE and how it could have a role in AD pathogenesis. They also summarize experimental animal and clinical data that demonstrate the therapeutic effect of RAGE inhibition and consider what these findings mean for human disease. EXPERT OPINION: RAGE has multiple ligands, including Aβ, that are increased in AD brains. Inhibiting RAGE-ligand interactions without activating receptor signaling can reduce multiple pathological pathways relevant for AD. Several RAGE inhibitors and modulators are now being tested as therapeutics for AD. Recent Phase II studies have established the good safety and tolerability of TTP448 with some evidence of positive benefit at lower dose. This suggests that further studies are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“Most recent clinical trials with Ab antibodies have not shown significant benefit [11].”
BackgroundSelf-citationAmyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611 · cited 1×
“This was followed shortly afterward by the identification of the amyloid precursor protein (APP) as being the protein from which Ab is derived, findings that led to the current era of AD research [5].”
BackgroundRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619 · cited 2×
“Both agents prevented Ab influx into brain, but FPS-ZM1 was more effective in lowering events occurring in the brain, such as BACE-1 expression, neuroinflammation and cerebral plaque load [37].”
BackgroundGlycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.
Yan, S. D., Chen, X., Schmidt, A. M., Brett, J., Godman, G., Zou, Y. S., Scott, C. W., Caputo, C., Frappier, T., & Smith, M. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7787 · Cited by 565
Cited by
The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
Sengupta, U., Nilson, A. N., & Kayed, R. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.035 · Cited by 740
Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease
Pugazhenthi, S., Qin, L., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.04.017 · Cited by 697
Perrone, A., Giovino, A., Benny, J., & Martinelli, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3818196 · Cited by 459
Oxidative Stress in Health and Disease
Reddy, V. P. (2023) · Biomedicines · doi:10.3390/biomedicines11112925 · Cited by 333
Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus
Khosla, S., Samakkarnthai, P., Monroe, D. G., & Farr, J. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00555-5 · Cited by 260
Nilson, A. N., English, K. C., Gerson, J. E., Barton Whittle, T., Nicolas Crain, C., Xue, J., Sengupta, U., Castillo-Carranza, D. L., Zhang, W., Gupta, P., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160912 · Cited by 167
“The NF B transcription factor increases the expression of HMGB1 and its receptor RAGE, increasing pro-inflammatory RAGE signaling by a feed-forward mechanism [57, 58].”
BackgroundDerk, J., MacLean, M., Juranek, J., & Schmidt, A. M. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000421 · Cited by 96
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
“Under normal physiological conditions, RAGE is expressed at low levels in endothelial cells (Walker et al., 2015), and soluble Aβ in the nanomolar range binds to RAGE and exerts its pathophysiologic cellular effects (Deane et al., 2003; Walker et al., 2015).”
BackgroundStochastic non-enzymatic modification of long-lived macromolecules - A missing hallmark of aging
Fedintsev, A., & Moskalev, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101097 · Cited by 72
RAGE Signaling in Skeletal Biology
Plotkin, L. I., Essex, A. L., & Davis, H. M. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00499-w · Cited by 54
Effects of RAGE inhibition on the progression of the disease in hSOD1G93A ALS mice
Liu, L., Killoy, K. M., Vargas, M. R., Yamamoto, Y., & Pehar, M. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.636 · Cited by 17
Metadata
- Authors
- Walker, D., Lue, L. F., Paul, G., Patel, A., & Sabbagh, M. N.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2015-01-14
- Volume
- 24
- Issue
- 3
- Pages
- 393-399
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2014928614
- Cited by
- 77
- References
- 19
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.